News for BioMarin Pharmaceutical Inc. (BMRN)

PR NewswireSAN RAFAEL, Calif., April 17, 2025 SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announce

BioMarin Pharmaceutical Inc. (BMRN) will announce its Q1 2025 financial results on May 1, 2025. CEO Alexander Hardy will host the conference call and we

MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme 'Access for all: Women and girls bleed too' and celebrate World Hemophilia Day. Today, women and girls with bleeding disorders (WGBDs) are still underdiagnosed and underserved. The global bleeding disorders community has the power-and the responsibility-to change this. Through recognition, diagnosis, treatment, and care, the quality of life of WGBDS will improve, and the bleeding disorders community will become stronger.

Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry […]

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Stock market downturns are traditionally the ideal time to go shopping for bargains.

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioMarin Pharmaceutical Inc.

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

On March 19, 2025, Erin Burkhart, Chief Accounting Officer at Biomarin Pharmaceutical Inc (BMRN), executed a sale of 1,295 shares of the company. Following this

Insight into Biomarin's robust product portfolio and expanding pipeline.Analysis of Biomarin's financial resilience and strategic growth initiatives.Understand

PR NewswireSAN RAFAEL, Calif., Feb. 24, 2025 SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ETCompany ParticipantsTraci McCarty - Head of...

BioMarin (BMRN) delivered earnings and revenue surprises of 26.03% and 4.97%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?